Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
Abstract This Summary of Research overviews the results of the VOLTAIRE-X study (NCT03210259), which looked at what happened when people with plaque psoriasis continually took the adalimumab reference product (adalimumab RP; known by the brand name Humira®) or switched three times between taking the...
Saved in:
Main Author: | Alan Menter (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
by: Nicolazzo D, et al.
Published: (2014) -
Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
by: Norman Saffra, et al.
Published: (2017) -
Voltaire
by: Morley, John, 1838-1923 -
Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
by: Annunziata Raimondo, MD, et al.
Published: (2021) -
The life of Voltaire
by: Hall, Evelyn Beatrice, 1868-1956